Earnings Summary

Rigel Pharmaceuticals Inc’s revenue jumped 55.78% since last year same period to $26.07Mn in the Q1 2023. On a quarterly growth basis, Rigel Pharmaceuticals Inc has generated -49.16% fall in its revenue since last 3-months.

Rigel Pharmaceuticals Inc’s net profit jumped 50.68% since last year same period to $-13.54Mn in the Q1 2023. On a quarterly growth basis, Rigel Pharmaceuticals Inc has generated -1066.17% fall in its net profits since last 3-months.

Rigel Pharmaceuticals Inc’s net profit margin jumped 68.34% since last year same period to -51.92% in the Q1 2023. On a quarterly growth basis, Rigel Pharmaceuticals Inc has generated -2000.39% fall in its net profit margins since last 3-months.

Rigel Pharmaceuticals Inc’s earning per share (EPS) estimates for the current quarter stand at -0.14 - a -7.69% fall from last quarter’s estimates.

Rigel Pharmaceuticals Inc’s earning per share (EPS) estimates for the current year stand at -0.14.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Rigel Pharmaceuticals Inc’s return on assets (ROA) stands at -0.2.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Rigel Pharmaceuticals Inc’s return on equity (ROE) stands at -6.99.